Anida Šehić

Dr. Anida Šehić


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SUSefika Umihanic
Sefika Umihanic
LLLora Novakovic Lackovic
Lora Novakovic Lackovic
LNLejla Alidzanovic Nurkanovic
Lejla Alidzanovic Nurkanovic
MKMedina Bandovic Kuduzovic
Medina Bandovic Kuduzovic
AŠAnida Šehić
Anida Šehić
NSNejra Selak
Nejra Selak
Background/Objectives: Squamous cell lung cancer (SCC) presents a significant treatment challenge due to its poor prognosis and limited therapeutic options. In many resource-limited countries, access to advanced molecular testing is often unavailable, making the identification of novel and reliable prognostic markers crucial for improving patient selection for systemic treatments. Methods: This single-center, retrospective study investigated the prognostic value of inflammatory biomarkers, including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), in 134 patients diagnosed with SCC. Patients were stratified into groups based on optimal cut-off values determined by ROC analysis for each biomarker. Results: Elevated levels of the SII, NLR, and PLR were significantly associated with shorter overall survival in patients with SCC (all p < 0.05). Conclusions: These easily accessible and cost-effective laboratory parameters are particularly valuable in settings where molecular testing is not available, aiding in the identification of high-risk patients and optimizing treatment selection for chemotherapy.